Fabry Disease clinical trials

Explore recruiting fabry disease clinical trials.

Recruiting fabry disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fabry Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.

Austria, France, Germany, Norway, Poland, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF MIGALASTAT HCL IN SUBJECTS WITH FABRY DISEASE AND AMENABLE GLA VARIANTS AND SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE TREATED WITH HEMODIALYSIS

Spain, France, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age with Fabry Disease who are treatment-naïve or Untreated for at Least 6 Months

Norway, Poland, France, Romania, Italy, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease – prospective randomized controlled phase III trial

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA Variants

Spain, Germany, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry disease and left ventricular hypertrophy

Italy, Greece, Netherlands, Denmark, Czechia, Austria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fabry Disease trials by city

Fabry Disease in Toronto Fabry Disease in Vancouver Fabry Disease in Montreal Fabry Disease in Calgary Fabry Disease in Edmonton Fabry Disease in Ottawa Fabry Disease in Winnipeg Fabry Disease in Quebec City Fabry Disease in Hamilton Fabry Disease in Kitchener Fabry Disease in London Fabry Disease in Halifax Fabry Disease in New York Fabry Disease in Los Angeles Fabry Disease in Chicago Fabry Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease